![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-20.00 | -0.16% | 12,106.00 | 12,120.00 | 12,122.00 | 12,190.00 | 12,024.00 | 12,080.00 | 999,558 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.98B |
RNS Number:6156O AstraZeneca PLC 13 August 2003 CRESTOR(R) RECEIVES FDA APPROVAL CRESTOR Significantly Lowers LDL Cholesterol by As Much As 63% AstraZeneca announced today that its new cholesterol-lowering medication, CRESTOR(R) (rosuvastatin calcium), which has been shown to lower LDL-cholesterol by up to 63 percent, has received approval from the U.S. Food and Drug Administration (FDA) as an adjunct to diet for the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. This follows the successful Advisory Committee Meeting held in the US on 9th July 2003 where the Committee voted unanimously to recommend the approval of CRESTOR. CRESTOR is the newest member of the cholesterol-lowering statin (HMG-CoA reductase inhibitors) class of drug therapy. In addition to its LDL (low-density lipoprotein) or "bad" cholesterol lowering effects, CRESTOR has been shown to provide a significant increase in HDL (high-density lipoprotein) or "good" cholesterol. "We are delighted with the approval of CRESTOR in the United States," said Sir Tom McKillop, Chief Executive Officer of AstraZeneca. "We believe that CRESTOR offers an important new treatment option for patients who are either untreated or not at target cholesterol levels." The FDA has approved the recommended usual starting dose of CRESTOR to be 10 mg once daily with a dose range of 5 to 40 mg available. Therapy with CRESTOR should be individualised according to goal of therapy and response. For patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20 mg start dose may be considered, and for special populations a 5 mg dose is also available. The clinical development program for CRESTOR is the largest program ever submitted to initially evaluate a statin. In multiple clinical studies, CRESTOR has been shown to be more effective in lowering LDL-cholesterol (LDL-C or 'bad cholesterol') than currently prescribed statins. CRESTOR 10mg gets significantly more patients to their LDL-C goal (both NCEP ATP III (US) and European) than atorvastatin 10mg and, in addition to the dramatic reductions seen in LDL-C, CRESTOR produces a significant increase in HDL-C ('good cholesterol'), as well as reducing total cholesterol and triglycerides. Evidence collected from over 24,000 patients who have taken CRESTOR demonstrates that it is well tolerated with a safety profile comparable to that of other statins. Guidelines issued by the National Cholesterol Education Program's Adult Treatment Panel III have substantially increased the number of patients eligible for cholesterol-lowering drug therapy from approximately 13 million to 36 million. Currently, it is estimated that more than 20 million Americans have an LDL goal of
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions